Table 3 Comparison of mean blood flow velocities (cm/s) in patients with diabetes before and after atorvastatin and placebo treatment.

	Group 1 (n = 15)			Group 2 (n = 15)			Group 3 (n = 15)
							NPDR (n = 8)			PDR (n = 7)
	Baseline	After 10 weeks	p Value*	Baseline	After 10 weeks	p Value*	Baseline	After 10 weeks	p Value*	Baseline	After 10 weeks	p Value*
OA
PSV	32.5 (5.8)	29.5 (5.0)	0.053	30.0 (7.1)	25.2 (5.6)	0.007†	33.6 (6.5)	32.6 (6.7)	0.57	30.5 (5.7)	31.1 (5.5)	0.81
EDV	6.7 (1.4)	6.5 (1.1)	0.32	6.3 (1.3)	6.1 (1.4)	0.43	6.7 (1.2)	6.6 (1.1)	0.52	6.3 (1.6)	6.3 (1.4)	0.91
RI	0.80 (0.06)	0.77 (0.05)	0.12	0.79 (0.05)	0.77 (0.04)	0.06	0.78 (0.06)	0.79 (0.06)	0.62	0.80 (0.06)	0.79 (0.05)	0.67
CRA
PSV	11.3 (1.9)	9.5 (1.4)	0.002†	9.2 (2.0)	7.8 (1.6)	0.01†	10.5 (2.1)	10.4 (2.0)	0.90	9.2 (1.9)	9.3 (2.0)	0.67
EDV	3.4 (0.7)	3.5 (0.5)	0.78	3.0 (0.6)	3.0 (0.4)	0.75	3.3 (0.4)	3.4 (0.5)	0.66	3.1 (0.5)	3.0 (0.4)	0.76
RI	0.69 (0.06)	0.62 (0.06)	0.003†	0.66 (0.08)	0.61 (0.08)	0.01†	0.68 (0.07)	0.69 (0.07)	0.88	0.66 (0.08)	0.67 (0.07)	0.90

CRA, central retinal artery; EDV, end diastolic velocity; NPDR, non‐proliferative diabetic retinopathy; OA, Opthalmic artery; PDR, proliferative diabetic retinopathy; PSV, Peak systolic velocity; RI, resistive index.

Values are mean (SD).

* p Value for comparison before and after atorvastatin and placebo treatment.

† Statistically significant.